Sally C. Medley

Array ( [id] => 2893144 [patent_doc_number] => 05272082 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1993-12-21 [patent_title] => 'Cytotoxic T-ALL cell lines and uses therefor' [patent_app_type] => 1 [patent_app_number] => 7/859927 [patent_app_country] => US [patent_app_date] => 1992-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 5 [patent_no_of_words] => 9964 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/272/05272082.pdf [firstpage_image] =>[orig_patent_app_number] => 859927 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3668056 [patent_doc_number] => 05599904 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-02-04 [patent_title] => 'Chimeric steroid hormone superfamily receptor proteins' [patent_app_type] => 1 [patent_app_number] => 7/845857 [patent_app_country] => US [patent_app_date] => 1992-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 16 [patent_no_of_words] => 13755 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/599/05599904.pdf [firstpage_image] =>[orig_patent_app_number] => 845857 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3067730 [patent_doc_number] => 05336489 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1994-08-09 [patent_title] => 'Treatment of allograft rejection with IL-2 receptor-specific cytotoxins' [patent_app_type] => 1 [patent_app_number] => 7/842463 [patent_app_country] => US [patent_app_date] => 1992-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 3927 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/336/05336489.pdf [firstpage_image] =>[orig_patent_app_number] => 842463 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3770903 [patent_doc_number] => 05756448 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-05-26 [patent_title] => 'Constitute activator of retinoid (CAR) receptor polypeptides' [patent_app_type] => 1 [patent_app_number] => 7/843350 [patent_app_country] => US [patent_app_date] => 1992-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 1 [patent_no_of_words] => 8422 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/756/05756448.pdf [firstpage_image] =>[orig_patent_app_number] => 843350 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3643422 [patent_doc_number] => 05683688 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-11-04 [patent_title] => 'Unglycosylated recombinant human lymphotoxin polypeptides and compositions' [patent_app_type] => 1 [patent_app_number] => 7/836765 [patent_app_country] => US [patent_app_date] => 1992-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 15937 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/683/05683688.pdf [firstpage_image] =>[orig_patent_app_number] => 836765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3118119 [patent_doc_number] => 05380712 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1995-01-10 [patent_title] => 'Truncated human serum albumin polypeptides as plasma expanding agents' [patent_app_type] => 1 [patent_app_number] => 7/944706 [patent_app_country] => US [patent_app_date] => 1992-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 11 [patent_no_of_words] => 4617 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/380/05380712.pdf [firstpage_image] =>[orig_patent_app_number] => 944706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3418072 [patent_doc_number] => 05453489 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1995-09-26 [patent_title] => 'Polypeptide fragments of fibronectin which can modulate extracellular matrix assembly' [patent_app_type] => 1 [patent_app_number] => 7/829462 [patent_app_country] => US [patent_app_date] => 1992-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 18 [patent_no_of_words] => 8638 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/453/05453489.pdf [firstpage_image] =>[orig_patent_app_number] => 829462 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3090394 [patent_doc_number] => 05312736 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1994-05-17 [patent_title] => 'Anticoagulant analogues of the tissue factor extrinsic pathway inhibitor (EPI) with reduced affinity for heparin' [patent_app_type] => 1 [patent_app_number] => 7/828920 [patent_app_country] => US [patent_app_date] => 1992-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 5371 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/312/05312736.pdf [firstpage_image] =>[orig_patent_app_number] => 828920 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3581190 [patent_doc_number] => 05498597 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1996-03-12 [patent_title] => 'FKBP-13, an FK506-binding immunophilin' [patent_app_type] => 1 [patent_app_number] => 7/822966 [patent_app_country] => US [patent_app_date] => 1992-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 7820 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/498/05498597.pdf [firstpage_image] =>[orig_patent_app_number] => 822966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3096798 [patent_doc_number] => 05298599 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1994-03-29 [patent_title] => 'Expression and purification of recombinant soluble tissue factor' [patent_app_type] => 1 [patent_app_number] => 7/816679 [patent_app_country] => US [patent_app_date] => 1992-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 5854 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/298/05298599.pdf [firstpage_image] =>[orig_patent_app_number] => 816679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3026465 [patent_doc_number] => 05348878 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1994-09-20 [patent_title] => 'Class I MHC-restricted T-T hybridomas, and a CD8-transfected BW5147, fusion partner therefor' [patent_app_type] => 1 [patent_app_number] => 7/814069 [patent_app_country] => US [patent_app_date] => 1991-12-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 16 [patent_no_of_words] => 13200 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/348/05348878.pdf [firstpage_image] =>[orig_patent_app_number] => 814069 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3063785 [patent_doc_number] => 05352588 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1994-10-04 [patent_title] => 'Streptococcal immunoglobulin a binding protein encoded by emmL2.2' [patent_app_type] => 1 [patent_app_number] => 7/813584 [patent_app_country] => US [patent_app_date] => 1991-12-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 3048 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/352/05352588.pdf [firstpage_image] =>[orig_patent_app_number] => 813584 [rel_patent_id] =>[rel_patent_doc_number] =>)